Display options
Cite
Zanis-Neto J, Ribeiro RC, Medeiros C, et al. Bone marrow transplantation for patients with Fanconi anemia: a study of 24 cases from a single institution. Bone Marrow Transplant. 1995;15(2):293-8
Zanis-Neto, J., Ribeiro, R. C., Medeiros, C., Andrade, R. J., Ogasawara, V., Hüsh, M., Magdalena, N., Friedrich, M. L., Bitencourt, M. A., & Bonfim, C. (1995). Bone marrow transplantation for patients with Fanconi anemia: a study of 24 cases from a single institution. Bone marrow transplantation, 15(2), 293-8.
Zanis-Neto, J, et al. "Bone marrow transplantation for patients with Fanconi anemia: a study of 24 cases from a single institution." Bone marrow transplantation vol. 15,2 (1995): 293-8.
Zanis-Neto J, Ribeiro RC, Medeiros C, Andrade RJ, Ogasawara V, Hüsh M, Magdalena N, Friedrich ML, Bitencourt MA, Bonfim C. Bone marrow transplantation for patients with Fanconi anemia: a study of 24 cases from a single institution. Bone Marrow Transplant. 1995 Feb;15(2):293-8. PMID: 7773221.
Copy Download .nbib Format: NLM
Share it on

Bone Marrow Transplant. 1995 Feb;15(2):293-8.

Bone marrow transplantation for patients with Fanconi anemia: a study of 24 cases from a single institution.

Bone marrow transplantation

J Zanis-Neto, R C Ribeiro, C Medeiros, R J Andrade, V Ogasawara, M Hüsh, N Magdalena, M L Friedrich, M A Bitencourt, C Bonfim

Affiliations

  1. Department of Internal Medicine, Hospital de Clinicas, Universidade Federal do Paraná, Curitiba, Brazil.

PMID: 7773221

Abstract

Although bone marrow transplantation (BMT) can eliminate the hematologic manifestations of Fanconi anemia (FA), patients are unusually susceptible to complications associated with the use of cyclophosphamide (CY) in the conditioning regimen. To investigate modifications of the conditioning regimen, we reviewed the records of 24 patients with FA who received an allogeneic BMT. All patients presented with severe pancytopenia. One patient was transplanted with overt leukemia as well. Donors were HLA-identical siblings in 22 cases and 1- and 2-antigen mismatched relatives in two cases, respectively. All conditioning regimens included CY 200 mg/kg in 10 patients; 140 mg/kg with or without antithymocyte globulin in 12 and 20 mg/kg with 400 cGy total body irradiation in two. GVHD prophylaxis comprised methotrexate and/or cyclosporine. Only one of 21 evaluable patients did not show signs of engraftment. Toxicities included grade III/IV mucositis in 20 patients, severe dermatitis in four and veno-occlusive disease in four. Acute GVHD (> or = grade II) occurred in nine of 22 patients. Four patients developed chronic GVHD. With a median follow-up time of 24 months, 14 of the 24 patients are alive with normal hematopoietic function. Eight of the 10 patients with matched sibling donors who were conditioned with CY 140 mg/kg are alive and well. We conclude that BMT is an effective treatment for FA. Conditioning regimens using lower doses of CY are associated with manageable toxicity and can potentially increase the survival rate of patients with HLA-matched donors.

MeSH terms

Publication Types

Grant support